Dr. Dan Sperling, M.D., D.A.B.R.

Specialist in advanced MRI-guided prostate imaging and treatment, founder of Sperling Prostate Center

Dr. Dan Sperling is a leader in the detection of prostate tumors through the use of image-guided technology. Dr. Sperling developed the 3T Multi-Parametric MRI – BlueLaser™ solutions. He specializes in AI and Magnetic Resonance Imaging (MRI) which he uses for tumor detection, targeted biopsies (MRI-Guided Biopsy; prostate mapping, and treatment).

Dr. Sperling serves as Medical Director and Chief of Interventional Uroradiology at the Sperling Prostate Center in Florida, as well as the Medical Director of its parent practice, the Sperling Medical Group.

Dr. Sperling is a member of the American Board of Radiology. Additionally, he is certified by the Society of Uroradiology, American Society of Laser Medicine and is an American Board of Radiology Diplomate. He completed a fellowship in oncologic PET/CT and interventional body imaging at the Albert Einstein College of Medicine at Montefiore Medical Center in New York. He completed a second fellowship in nuclear radiology at the New York University School of Medicine at Northshore University Hospital.

Dr. Sperling speaks nationally about prostate cancer detection and treatment. Most recently Dr. Sperling lectured to over 150 urologists at NYU Medical Center at the conference for Advances in Prostate Imaging and Focal Ablative Treatment of Prostate Cancer.

“Our Center is one of a handful of U.S. facilities with a highly powerful magnet capable of shorter imaging times and a range of special features for scanning all ages,” says Dr. Sperling. “With our forward-looking imaging technology, including Artificial Intelligence (AI) applications, and our team approach to noninvasive disease detection, diagnosis, and image-guided treatment, we are on the leading edge of significant change in medical practice.” The Sperling Medical Group was cited in Life Force, a 2022 book by Tony Robbins, et al. on new breakthroughs in precision medicine.

Specialty areas of practice

Dr. Sperling uses a high definition, multi-parametric MRI to produce detailed images of the prostate. His MRI technology provides precise images that detail the size and dimensions of the gland, allowing him to map the prostate with superior accuracy. In addition, Dr. Sperling performs several tests during the MRI to identify potential tumors and to mark these regions of interest. The results display the size and location of possible tumors in unprecedented detail. Any suspected tumors can be targeted and sampled through either MRI-Guided Biopsy or MRI/Ultrasound Fusion Biopsy. By combining the biopsy results with the prostate map, Dr. Sperling can help patients and doctors improve cancer detection and treatment planning, whether the treatment of choice is surgery, radiation or ablation, watchful waiting or focal therapy.

Dr. Sperling offers several methods to treat prostate tumors, including MRI-Guided Prostate Laser Ablation, a procedure he helped to pioneer. This revolutionary treatment represents a major shift from radical surgery and radiation. MRI-Guided prostate Laser Ablation is a minimally invasive procedure that can minimize many of the risks associated with traditional forms of prostate treatment, such as impotence (erectile dysfunction) and incontinence (loss of bladder control). MRI-Guided Laser Ablation requires no inpatient surgery.

Dr. Eric Walser, M.D., F.A.C.R.

Leading authority and researcher in minimally invasive focal therapy for prostate cancer and BPH, former Professor and Chairman of Radiology at University of Texas

Dr. Eric Walser is recognized as a pioneer in focal ablation of prostate cancer. As a clinician, he is an expert in minimally invasive image-guided treatments for both prostate cancer and benign prostatic hyperplasia (BPH). As a researcher, Dr. Walser has demonstrated the safety and effectiveness of focal treatment, with published results on over 400 focally treated patients.

Dr. Walser comes to Sperling Prostate Center after serving over 10 years as Professor and Chairman of Radiology at University of Texas. During his tenure, he began the institutional prostate ablation program. In 2019, he and Dr. Dan Sperling were members of an international panel of experts to develop a consensus statement on MRI-guided focal laser ablation of prostate cancer. They have been friends and collaborators in men’s health ever since.

Dr. Walser is a member of numerous professional societies, including the American Board of Radiology, the Radiological Society of North American, the Society of Interventional Radiology, the Congress of Interventional Radiology of Europe and others. He is a Diplomat of the American Board of Radiology, and a Fellow of the American College of Radiology. He completed his residency in Diagnostic Radiology and his fellowship in Interventional Radiology & Body Imaging at Indiana University Medical Center in 1993.

Dr. Walser began diagnosing and treating prostate cancer in 2011 at the Mayo Clinic in Florida. Since then, he has treated over 500 patients with prostate cancer and performed thousands of procedures for the diagnosis and treatment of prostate disease.

Dr. Walser is widely published and has been interviewed in the Houston media for his work in prostate cancer. He is the recipient of numerous awards for his teaching and innovative research. He was a panelist on “The Doctor’s show” on NBC discussing the use of laser in ablating tumors. With over 25 years of clinical experience, Dr. Walser continues to research new clinical technologies and methods.

Dr. Walser is excited to bring his experience and talents to the Sperling Prostate Center. He states, “As someone who has spent many years in leadership and academic institutions, it’s time to step away from that and devote that expertise to patients in a community practice.”

Specialty areas of practice

Dr. Walser is committed to improving patient lives through the benefits of focal treatments for prostate cancer and BPH. Most recently, he is a key developer of MRI-directed Ultrasound Guided Transperineal Focal Laser Ablation (TPLA), adding this new approach to focal therapies at the Sperling Prostate Center. He continues to explore cutting edge technologies in MRI procedures and the use of AI for prostate diagnosis and precision therapy.

Interested readers can access topical published papers at the following links:

• “Anatomic and Clinical Effects of Focal Laser Ablation of the Prostate on Symptomatic Benign Prostatic Hyperplasia” (2025) https://doi.org/10.3390/cancers17030475
• “Laser-focused ablative therapy for prostate cancer and benign prostatic hyperplasia: A review of current applications and future directions” (2025) https://pubmed.ncbi.nlm.nih.gov/40246600/
• “Focal Laser Ablation of Prostate Cancer: Results in 120 Patients with Low- to Intermediate-Risk Disease” (2019) https://pubmed.ncbi.nlm.nih.gov/30819483/
• “MRI-Guided Prostate Interventions” (2016) https://www.ajronline.org/doi/full/10.2214/AJR.16.16663